STOCK TITAN

PLUS THERAPEUTICS (PSTV) director awarded new stock options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. director Ronald Asbury Andrews reported new equity compensation awards, not open‑market trades. He received stock options for 1,600 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036, and an additional option for 3,686 shares at the same exercise price and expiration date.

He also received 3,686 Restricted Stock Units, each representing one share of Common Stock. According to the footnotes, the RSUs vest in four equal quarterly installments starting on July 1, 2026, while one option grant vests monthly over 12 months (with full vesting by the company’s 2027 Annual Stockholder Meeting) and the other vests monthly over 24 months.

Positive

  • None.

Negative

  • None.
Insider ANDREWS RONALD ASBURY
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units 3,686 $0.00 --
Grant/Award Stock Option (Right to Buy) 3,686 $0.00 --
Grant/Award Stock Option (Right to Buy) 1,600 $0.00 --
Holdings After Transaction: Restricted Stock Units — 3,686 shares (Direct, null); Stock Option (Right to Buy) — 3,686 shares (Direct, null)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. The options vest monthly over 24 months from the grant date in substantially equaly monthly increments.
Option grant 1 1,600 shares at $5.76 Stock option exercise price and size, expiring May 14, 2036
Option grant 2 3,686 shares at $5.76 Second stock option award, same exercise price and expiration
RSU grant 3,686 RSUs Each RSU equals one share of Common Stock
RSU vesting start July 1, 2026 First 1/4 of RSUs vest; remaining vest quarterly thereafter
Option vesting 12 months Monthly over 12 months Fully vests by 2027 Annual Stockholder Meeting, subject to service
Option vesting 24 months Monthly over 24 months Second option grant vests in equal monthly installments
Option expiration May 14, 2036 Expiration date for both stock option awards
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option financial
"The options vest monthly over 12 months from the grant date"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Annual Stockholder Meeting financial
"provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
exercise price financial
"conversion_or_exercise_price": "5.7600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ANDREWS RONALD ASBURY

(Last)(First)(Middle)
6420 LEVIT GREEN BOULEVARD
SUITE 310

(Street)
HOUSTON TEXAS 77021

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$0(1)05/14/2026A3,686 (1) (1)Common Stock3,686$03,686D
Stock Option (Right to Buy)$5.7605/14/2026A3,686 (2)05/14/2036Common Stock3,686$03,686D
Stock Option (Right to Buy)$5.7605/14/2026A1,600 (3)05/14/2036Common Stock1,600$01,600D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
2. The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.
3. The options vest monthly over 24 months from the grant date in substantially equaly monthly increments.
Andrew Sims, as attorney-in-fact05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PLUS THERAPEUTICS (PSTV) report for Ronald Asbury Andrews?

Ronald Asbury Andrews reported equity compensation awards, not market trades. He received stock options for 1,600 shares and 3,686 shares of Common Stock at a $5.76 exercise price, plus 3,686 Restricted Stock Units that settle in shares as they vest over time.

Were the PSTV Form 4 transactions open-market buys or sells of PLUS THERAPEUTICS stock?

The Form 4 shows no open-market buys or sells. All three transactions are coded as awards (Code A), representing grants of stock options and Restricted Stock Units to a director as compensation, rather than discretionary purchases or sales in the public market.

What stock option terms did PLUS THERAPEUTICS (PSTV) grant to director Ronald Asbury Andrews?

PLUS THERAPEUTICS granted Andrews two stock option awards. One covers 1,600 shares and the other 3,686 shares of Common Stock, both with a $5.76 exercise price per share and an expiration date of May 14, 2036, subject to specified vesting schedules in the footnotes.

How do the Restricted Stock Units granted to the PLUS THERAPEUTICS (PSTV) director vest?

The 3,686 Restricted Stock Units vest in four equal quarterly installments. Vesting begins with one-quarter of the RSUs on July 1, 2026, and the remaining three-quarters vest in substantially equal quarterly amounts thereafter, assuming continued service through each applicable vesting date.

What are the vesting conditions for the new PLUS THERAPEUTICS (PSTV) stock options?

One option grant vests monthly over 12 months from the grant date and becomes fully vested at the 2027 Annual Stockholder Meeting. The other vests in substantially equal monthly installments over 24 months, both contingent on the director’s continued service to the company.

What does each RSU represent in the PLUS THERAPEUTICS (PSTV) Form 4 filing?

Each Restricted Stock Unit represents a contingent right to receive one share of PLUS THERAPEUTICS Common Stock. Shares are delivered as the RSUs vest under the quarterly schedule described, tying the director’s compensation to ongoing service and future share performance over the vesting period.